Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

XML

Spondyloarthritis

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Online download statistics by month:

Online download statistics by month: April 2021 to January 2023

	Abstract	Full	Pdf
Apr 2021	979	977	366
May 2021	1616	1588	827
Jun 2021	937	923	478
Jul 2021	1360	1357	515
Aug 2021	989	982	413
Sep 2021	552	537	250
Oct 2021	690	684	248
Nov 2021	723	708	291
Dec 2021	671	660	227
Jan 2022	555	562	237
Feb 2022	573	547	258
Mar 2022	1621	1627	328
Apr 2022	1476	1475	277
May 2022	1448	1439	314
Jun 2022	1457	1465	248
Jul 2022	827	813	186
Aug 2022	706	683	263
Sep 2022	668	667	253
Oct 2022	723	698	210
Nov 2022	821	796	222
Dec 2022	459	437	164
Jan 2023	549	531	208
Total	20400	20156	6783